NEW YORK (GenomeWeb) – Amoy Diagnostics, Premia Holdings, and Loxo Oncology today announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.
As part of the deal, China-based AmoyDx and Tokyo-headquartered Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development. AmoyDx's multigene PCR and next-generation sequencing panels will be used to identify patients with RET genetic alteration.
Financial and other terms of the agreement were not disclosed.